Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Efficacy of VB15010 Tablets In Patients With Advanced Solid Tumors

NCT06819215 is registered in ClinicalTrials.gov with Zhejiang Yangli Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06819215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06819215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Efficacy of VB15010 Tablets In Patients With Advanced Solid Tumors
Lead sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 30, 2024
Completion date
March 30, 2026
Enrollment
188 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary cancer, breast cancer, cancer, colorectal cancer, neoplasms, neoplasms, breast, ovarian neoplasms, pancreatic cancer, parp, prostatic cancer, tumor